1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Hypertension in 42 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study, the effect of a subdose of fasudil, a selective ROCK inhibitor, on systemic hypertension and myocardium fibrosis induced by aldosterone was investigated in uninephrectomized Sprague-Dawley rats (SD)." | 7.77 | Subdose of fasudil suppresses myocardial fibrosis in aldosterone-salt-treated uninephrectomized rats. ( Guo, P; Masaki, T; Mori, H; Nishiyama, A; Wu, C, 2011) |
| "These results suggest that fasudil has beneficial effects on retinal vascular complications associated with chronic hypertension." | 7.74 | Vasodilator effects of fasudil, a Rho-kinase inhibitor, on retinal arterioles in stroke-prone spontaneously hypertensive rats. ( Ishii, K; Kametaka, S; Mori, A; Nakahara, T; Okamura, N; Saito, M; Sakamoto, K, 2007) |
| " A selective Rho-kinase inhibitor, fasudil, has recently been shown to improve renal damage resulting from hypertensive glomerulosclerosis, unilateral ureteral obstruction (for interstitial renal fibrosis) and subtotal nephrectomy." | 4.83 | Molecular mechanisms and therapeutic strategies of chronic renal injury: role of rho-kinase in the development of renal injury. ( Hayashi, K; Homma, K; Kanda, T; Saruta, T; Sugano, N; Wakino, S, 2006) |
| "Twenty 12-week-old healthy male Sprague-Dawley rats were randomly divided into groups A (control), B (hypertension) and C (fasudil treatment)." | 3.78 | [Fasudil improves erectile function of hypertensive rats]. ( Chen, F; Cheng, Y; Jiang, R; Ma, ZP; Yang, HF, 2012) |
| " In the present study, the effect of a subdose of fasudil, a selective ROCK inhibitor, on systemic hypertension and myocardium fibrosis induced by aldosterone was investigated in uninephrectomized Sprague-Dawley rats (SD)." | 3.77 | Subdose of fasudil suppresses myocardial fibrosis in aldosterone-salt-treated uninephrectomized rats. ( Guo, P; Masaki, T; Mori, H; Nishiyama, A; Wu, C, 2011) |
| "These results suggest that fasudil has beneficial effects on retinal vascular complications associated with chronic hypertension." | 3.74 | Vasodilator effects of fasudil, a Rho-kinase inhibitor, on retinal arterioles in stroke-prone spontaneously hypertensive rats. ( Ishii, K; Kametaka, S; Mori, A; Nakahara, T; Okamura, N; Saito, M; Sakamoto, K, 2007) |
| "To determine the effects of fasudil, a Rho-kinase inhibitor, on mineralocorticoid-induced myocardial remodeling, we investigated whether fasudil would suppress myocardial fibrosis and inflammation in deoxycorticosterone-acetate (DOCA)/salt hypertensive rats." | 3.74 | Fasudil attenuates myocardial fibrosis in association with inhibition of monocyte/macrophage infiltration in the heart of DOCA/salt hypertensive rats. ( Inoue, H; Ishimaru, K; Kagitani, S; Takabayashi, D; Takata, M; Ueno, H, 2007) |
| "We investigated the effects of fasudil, a Rho kinase inhibitor, on hypertension in spontaneously hypertensive rats and on the catecholamine synthetic pathway." | 3.74 | Fasudil attenuates sympathetic nervous activity in the adrenal medulla of spontaneously hypertensive rats. ( Hayashi, M; Kobayashi, S; Kumai, T; Matsumoto, N; Nakaya, S; Takeba, Y; Tsuzuki, Y; Yanagida, Y, 2007) |
| "Hypertensive cardiac hypertrophy is associated with reduced coronary flow reserve, but its impact on coronary flow regulation and vasomotor function remains incompletely understood and requires further investigation." | 1.46 | Enhanced endothelin-1/Rho-kinase signalling and coronary microvascular dysfunction in hypertensive myocardial hypertrophy. ( Hein, TW; Kuo, L; Lu, G; Ren, Y; Tsai, SH; Xu, X, 2017) |
| "Fasudil treatment significantly ameliorated those DHF-related myocardial changes." | 1.35 | Long-term inhibition of Rho-kinase ameliorates diastolic heart failure in hypertensive rats. ( Fukui, S; Fukumoto, Y; Kagaya, Y; Nawata, J; Saji, K; Shimokawa, H; Shinozaki, T; Suzuki, J; Tawara, S, 2008) |
| " H-7 produced a shift to the right of the dose-response curve for the PKC activator, 12-o-tetradecanoylphorbol-13-acetate (TPA) in the case of SHR aortas, while no such shift was noted in tissues from WKY." | 1.28 | Effects of H-7 (protein kinase inhibitor) and phorbol ester on aortic strips from spontaneously hypertensive rats. ( Iwasaki, T; Miyata, S; Morita, S; Nagai, K; Shibata, R, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.76) | 18.7374 |
| 1990's | 7 (16.67) | 18.2507 |
| 2000's | 19 (45.24) | 29.6817 |
| 2010's | 14 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsai, SH | 1 |
| Lu, G | 1 |
| Xu, X | 2 |
| Ren, Y | 1 |
| Hein, TW | 1 |
| Kuo, L | 1 |
| Chan, SL | 1 |
| Cipolla, MJ | 1 |
| Ocaranza, MP | 1 |
| Fierro, C | 1 |
| Jalil, JE | 1 |
| Moya, J | 1 |
| Gonzalez, L | 1 |
| Molina, C | 1 |
| Mancilla, C | 1 |
| Vaněčková, I | 2 |
| Behuliak, M | 2 |
| Hojná, S | 1 |
| Kopkan, L | 1 |
| Kadlecová, M | 1 |
| Zicha, J | 2 |
| Yuan, TY | 1 |
| Chen, D | 1 |
| Chen, YC | 1 |
| Zhang, HF | 1 |
| Niu, ZR | 1 |
| Jiao, XZ | 1 |
| Xie, P | 1 |
| Fang, LH | 1 |
| Du, GH | 1 |
| Snelder, N | 1 |
| Ploeger, BA | 1 |
| Luttringer, O | 1 |
| Rigel, DF | 1 |
| Fu, F | 1 |
| Beil, M | 1 |
| Stanski, DR | 1 |
| Danhof, M | 1 |
| Vavřínová, A | 1 |
| Bencze, M | 1 |
| Polgárová, K | 1 |
| Ergang, P | 1 |
| Kuneš, J | 1 |
| Chan, CK | 1 |
| Mak, JC | 1 |
| Man, RY | 1 |
| Vanhoutte, PM | 1 |
| Ying, Z | 1 |
| Yue, P | 1 |
| Zhong, M | 1 |
| Sun, Q | 1 |
| Mikolaj, M | 1 |
| Wang, A | 1 |
| Brook, RD | 1 |
| Chen, LC | 1 |
| Rajagopalan, S | 1 |
| Büssemaker, E | 1 |
| Herbrig, K | 1 |
| Pistrosch, F | 1 |
| Palm, C | 1 |
| Passauer, J | 1 |
| de Frutos, S | 1 |
| Caldwell, E | 1 |
| Nitta, CH | 1 |
| Kanagy, NL | 1 |
| Wang, J | 1 |
| Wang, W | 1 |
| Walker, MK | 1 |
| Gonzalez Bosc, LV | 1 |
| Ray, P | 1 |
| Wright, J | 1 |
| Adam, J | 1 |
| Boucharens, S | 1 |
| Black, D | 1 |
| Brown, AR | 1 |
| Epemolu, O | 1 |
| Fletcher, D | 1 |
| Huggett, M | 1 |
| Jones, P | 1 |
| Laats, S | 1 |
| Lyons, A | 1 |
| de Man, J | 1 |
| Morphy, R | 1 |
| Sherborne, B | 1 |
| Sherry, L | 1 |
| Straten, Nv | 1 |
| Westwood, P | 1 |
| York, M | 1 |
| Guo, P | 1 |
| Wu, C | 1 |
| Masaki, T | 1 |
| Mori, H | 1 |
| Nishiyama, A | 1 |
| Ma, ZP | 1 |
| Jiang, R | 1 |
| Cheng, Y | 1 |
| Yang, HF | 1 |
| Chen, F | 1 |
| Inoue, S | 1 |
| Saito, M | 4 |
| Takenaka, A | 2 |
| Ohmasa, F | 2 |
| Dimitriadis, F | 2 |
| Tsounapi, P | 2 |
| Sejima, T | 1 |
| Shimizu, S | 2 |
| Kinoshita, Y | 2 |
| Satoh, K | 2 |
| Kitatani, K | 1 |
| Mukai, Y | 2 |
| Higashi, M | 1 |
| Shimokawa, H | 4 |
| Hattori, T | 1 |
| Hiroki, J | 1 |
| Morikawa, K | 1 |
| Ichiki, T | 1 |
| Takahashi, S | 1 |
| Takeshita, A | 2 |
| Kanda, T | 3 |
| Wakino, S | 3 |
| Hayashi, K | 3 |
| Homma, K | 3 |
| Ozawa, Y | 1 |
| Saruta, T | 3 |
| Nakayama, M | 1 |
| Amano, M | 1 |
| Kawabata, S | 1 |
| Kaibuchi, K | 1 |
| Takefuji, M | 1 |
| Jarajapu, YP | 1 |
| Knot, HJ | 1 |
| Yoshioka, K | 1 |
| Tatematsu, S | 1 |
| Hasegawa, K | 1 |
| Takamatsu, I | 1 |
| Sugano, N | 2 |
| Nishikimi, T | 2 |
| Matsuoka, H | 1 |
| Chapados, R | 1 |
| Abe, K | 1 |
| Ihida-Stansbury, K | 1 |
| McKean, D | 1 |
| Gates, AT | 1 |
| Kern, M | 1 |
| Merklinger, S | 1 |
| Elliott, J | 1 |
| Plant, A | 1 |
| Jones, PL | 1 |
| Okamura, N | 1 |
| Mori, A | 1 |
| Sakamoto, K | 1 |
| Kametaka, S | 1 |
| Nakahara, T | 1 |
| Ishii, K | 1 |
| Ishimaru, K | 1 |
| Ueno, H | 1 |
| Kagitani, S | 1 |
| Takabayashi, D | 1 |
| Takata, M | 1 |
| Inoue, H | 1 |
| Kumai, T | 1 |
| Takeba, Y | 1 |
| Matsumoto, N | 1 |
| Nakaya, S | 1 |
| Tsuzuki, Y | 1 |
| Yanagida, Y | 1 |
| Hayashi, M | 1 |
| Kobayashi, S | 1 |
| Fukui, S | 1 |
| Fukumoto, Y | 1 |
| Suzuki, J | 1 |
| Saji, K | 1 |
| Nawata, J | 1 |
| Tawara, S | 1 |
| Shinozaki, T | 1 |
| Kagaya, Y | 1 |
| Neusser, M | 1 |
| Tepel, M | 1 |
| Golinski, P | 1 |
| Zhu, Z | 1 |
| Rahn, KH | 1 |
| Spieker, C | 1 |
| Zidek, W | 1 |
| Nakane, H | 1 |
| Yao, H | 1 |
| Ibayashi, S | 1 |
| Kitazono, T | 1 |
| Ooboshi, H | 1 |
| Uchimura, H | 1 |
| Fujishima, M | 1 |
| Chan, JY | 1 |
| Chang, JW | 1 |
| Chan, SH | 1 |
| Masumoto, A | 1 |
| Hirooka, Y | 1 |
| Hironaga, K | 1 |
| Setoguchi, S | 1 |
| Kuriyama, S | 1 |
| Nakamura, K | 1 |
| Horiguchi, M | 1 |
| Uchida, H | 1 |
| Sakai, O | 1 |
| Soloviev, AI | 1 |
| Bershtein, SA | 1 |
| Shibata, R | 1 |
| Morita, S | 1 |
| Nagai, K | 1 |
| Miyata, S | 1 |
| Iwasaki, T | 1 |
| Hano, T | 1 |
| Shiotani, M | 1 |
| Baba, A | 1 |
| Ura, M | 2 |
| Nakamura, Y | 1 |
| Tomobuchi, Y | 1 |
| Nishio, I | 2 |
| Masuyama, Y | 3 |
| Tsuda, K | 2 |
| Inariba, H | 1 |
| Kanayama, Y | 1 |
| Takaori, K | 1 |
| Itoh, S | 1 |
| Inoue, T | 1 |
| Takeda, T | 1 |
| Shima, H | 1 |
| Takeda, J | 1 |
| Kimura, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Early Intracoronary Administration of Fasudil Hydrochloride on Myocardial Perfusion in the Primary PCI of ST-elevation Myocardial Infarction: an Prospective, Randomized and Multicenter Trial[NCT03753269] | Phase 4 | 600 participants (Anticipated) | Interventional | 2019-07-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Hypertension
| Article | Year |
|---|---|
[Involvement of small GTPase Rho and Rho-kinase in the pathogenesis of hypertension and hypertensive target organ damage].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Angina Pectoris; Animals; Arteriosclerosis; C | 2004 |
Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effect of rho-kinase inhibitor in hypertensive glomerulosclerosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Pressure; Collagen; Disease Models, An | 2006 |
Molecular mechanisms and therapeutic strategies of chronic renal injury: role of rho-kinase in the development of renal injury.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Cyclin-Dependent Kinase Inhi | 2006 |
[Role of the Rho/Rho-kinase pathway in the development of hypertensive glomerulosclerosis: renoprotective effect of Rho-kinase inhibitor in hypertensive glomerulosclerosis and its molecular mechanism].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Glomerulosclerosis, | 2006 |
1 trial available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Hypertension
| Article | Year |
|---|---|
Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Enzyme Inhibitors; Female; Forearm; Humans; Hypertens | 2001 |
37 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Hypertension
| Article | Year |
|---|---|
Enhanced endothelin-1/Rho-kinase signalling and coronary microvascular dysfunction in hypertensive myocardial hypertrophy.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arterioles; Cardiomegaly; Endothelin-1; Endo | 2017 |
Treatment with low dose fasudil for acute ischemic stroke in chronic hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cerebrovascular Circulation; Chronic Disease | 2017 |
Rho kinase activation in circulating leukocytes is related to hypertensive myocardial remodeling.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Atrial Remodeling; Blood Pressure; Cardiomeg | 2018 |
Exaggerated blood pressure response to fasudil or nifedipine in hypertensive Ren-2 transgenic rats: role of altered baroreflex.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Baroreflex; Blood Pressure; Calcium Channel | 2019 |
A novel hypertensive crisis rat model established by excessive norepinephrine infusion and the potential therapeutic effects of Rho-kinase inhibitors on it.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antihypertensive Agents; Blood Pressure; Hyp | 2019 |
Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amiloride; Amlodipine; Animals; Atropine; Enalapril; | 2014 |
Ontogenetic changes in contribution of calcium sensitization and calcium entry to blood pressure maintenance of Wistar-Kyoto and spontaneously hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arteries; Blood Pressure; Calcium; Calcium C | 2015 |
Rho kinase inhibitors prevent endothelium-dependent contractions in the rat aorta.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Antihypertensive Agents; Aorta, Thor | 2009 |
Air pollution and cardiac remodeling: a role for RhoA/Rho-kinase.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Atmosphere Exposure Chambers | 2009 |
Role of rho-kinase in the regulation of vascular tone in hypertensive renal transplant recipients.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Case-Control Studies; Dose-Response Relationship, Dru | 2009 |
NFATc3 contributes to intermittent hypoxia-induced arterial remodeling in mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Aorta, Thoracic; Bosentan; Dioxoles; | 2010 |
Optimisation of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amines; Animals; Disease Models, Animal; Hypertension | 2011 |
Subdose of fasudil suppresses myocardial fibrosis in aldosterone-salt-treated uninephrectomized rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aldosterone; Animals; Antihypertensive Agents; Biomar | 2011 |
[Fasudil improves erectile function of hypertensive rats].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Hypertension; Male; Penile Erection; Rats; R | 2012 |
Hydroxyfasudil ameliorates bladder dysfunction in male spontaneously hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Hypertension; Male; Muscle Contraction; Musc | 2012 |
Hydroxyfasudil ameliorates penile dysfunction in the male spontaneously hypertensive rat.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cyclic GMP; Erectile Dysfunction; Gene Expre | 2012 |
Fasudil improves the endothelial dysfunction in the aorta of spontaneously hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Aorta; Endothelium, Vascular; Gene Expressio | 2012 |
[Involvement of Rho-kinase in hypertensive vascular disease--a novel therapeutic target in hypertension].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Vessels; Cardiovascular Diseases; Hype | 2002 |
Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Aorta, Thoracic; Cardiomegal | 2003 |
Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Pressure; Cell Cycle Proteins; Cell Di | 2003 |
Relative contribution of Rho kinase and protein kinase C to myogenic tone in rat cerebral arteries in hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Alkaloids; Amides; Animals; Benzophenanthridines; Blo | 2005 |
Rho-kinase as a molecular target for insulin resistance and hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetylcholine; Animals; Arterioles; Cell Line; Glucos | 2006 |
ROCK controls matrix synthesis in vascular smooth muscle cells: coupling vasoconstriction to vascular remodeling.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Animals; Blood Vessels; Cell Adhesion; Cell S | 2006 |
Vasodilator effects of fasudil, a Rho-kinase inhibitor, on retinal arterioles in stroke-prone spontaneously hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Analysis of Variance; Animals; Blood Pressure; Dose-R | 2007 |
Fasudil attenuates myocardial fibrosis in association with inhibition of monocyte/macrophage infiltration in the heart of DOCA/salt hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Pressure; Cytokines; Desoxycorticoster | 2007 |
Fasudil attenuates sympathetic nervous activity in the adrenal medulla of spontaneously hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adrenal Medulla; Animals; Blood Pressure; Blotting, W | 2007 |
Long-term inhibition of Rho-kinase ameliorates diastolic heart failure in hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blotting, Western; Disease Models, Animal; D | 2008 |
Protein kinase C and calcium distribution in vascular smooth muscle cells from spontaneously hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Calcium; Calcium-Transporting ATPases; Cells | 1993 |
Protein kinase C modulates ischemia-induced amino acids release in the striatum of hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amino Acids; Animals; Brain Ischemia; Corpus Striatum | 1998 |
Role of calcium/calmodulin-dependent protein kinases in expression of Fos protein in the nucleus tractus solitarii after sustained hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Baroreflex; Calcium-Calmodulin-Dependent Pro | 2000 |
Decreased insulin-sensitive Ca2+ transport in cultured vascular smooth muscle cells from spontaneously hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amiloride; Animals; Biological Transport; Calcium; Ca | 1992 |
The contractile apparatus in vascular smooth muscle cells of spontaneously hypertensive rats possess increased calcium sensitivity: the possible role of protein kinase C.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Calcium; Hypertension; Isoquinolines; Muscle | 1992 |
Effects of H-7 (protein kinase inhibitor) and phorbol ester on aortic strips from spontaneously hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Aorta, Thoracic; Calcimycin; | 1990 |
Contribution of calmodulin and protein kinase C to renin release in spontaneously hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Calmodulin; Hypertension; In Vitro Technique | 1990 |
Effects of a protein kinase C inhibitor (H-7) on norepinephrine release from vascular adrenergic neurons in spontaneously hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Pressure; Blood Vessels; Electric Stim | 1990 |
Intracellular pH in platelets from spontaneously hypertensive rats and Wistar-Kyoto rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Platelets; Hydrogen-Ion Concentration; | 1988 |
Protein kinase C-dependent and calmodulin-dependent regulation of neurotransmitter release and vascular responsiveness in spontaneously hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Pressure; Blood Vessels; Calmodulin; E | 1988 |